Optellum vs Riverain Technologies
Updated October 19, 2026
Chest CT scans often reveal lung nodules, small spots that are usually harmless but sometimes early cancer, and hospitals struggle both to track them and to decide which ones need a biopsy. Optellum and Riverain Technologies both sell FDA-cleared AI for this problem, but buyers often miss that they serve different people: Optellum scores each nodule's cancer risk for the lung clinic, while Riverain helps radiologists spot findings during the read. Because health systems often weigh one against the other, we compared them directly.
Our analysts compared Optellum and Riverain Technologies on main job, users, product depth, rollout, and payment, using the HIR review of each company and each vendor's own announcements this year. In the following sections, we compare them in one table, describe the program each suits, and list each company's recent news.
Optellum vs Riverain Technologies at a glance, October 2026
| What buyers weigh | Optellum | Riverain Technologies |
|---|---|---|
| Pricing model | A custom contract quoted by Optellum. Medicare pays for use of its Lung Cancer Prediction AI under its own CPT codes, 0721T and 0722T. | Software licenses for ClearRead CT and X-ray modules, priced by site and volume. |
| What drives cost | Number of sites and CT volume, whether scanning reports for incidental nodules is included, PACS and EHR connection, and expected Medicare billing. | Number of sites, scan types (CT or X-ray), volume, and setup (on-site or cloud). |
| Main job | Finds patients with lung nodules in radiology reports and gives each nodule a cancer risk score from the CT scan. | FDA-cleared ClearRead tools that help detect lung disease on chest CT and X-ray. |
| Main user | Pulmonology and thoracic teams deciding between more scans, biopsy, and treatment. | Radiologists reading chest CT and X-ray in their usual viewer. |
| Where it works | Across a health system's reports and its nodule clinic, with modules that link imaging to treatment decisions. | Inside PACS and the viewer on each chest read, on site or in the cloud. |
| Product depth | Scores 8.1 for its lung nodule AI. Higher score | Scores 7.3 for ClearRead thoracic AI depth. |
| Results | Scores 7.4 on earlier diagnosis and fewer biopsies. | Scores 7.4 on chest detection on daily reading lists. |
| Rollout | Scores 7.0 on fitting into nodule clinics. | Scores 6.9 on PACS and viewer rollout. |
| Time to full value | About 8 to 17 months | Not published |
| What you need first | Pulmonology or nodule program lead. | A radiology lead and imaging IT time for the PACS connection. |
| Deal-breaker | You do few chest CT scans. | Your site lacks imaging IT staff or a radiology lead. |
| Pricing clarity score | 6.5 | 6.8 Clearer pricing |
| HIR overall score | 7.4, Recommend. | 7.3, Recommend. |
| Best for | Health systems running lung nodule clinics or incidental nodule follow-up programs. | Hospitals and imaging centers focused on finding lung nodules and chest disease on CT and X-ray. |
| Not a fit for | Radiology groups shopping for broad triage AI across many findings. | Sites whose main need is triage across specialties for stroke or pulmonary embolism. |
Which fits which buyer
Picture who opens the results first, the radiologist or the lung clinic.
Choose Optellum if
- You run a lung nodule clinic or an incidental nodule follow-up program.
- Pulmonologists need a cancer risk score to choose between scans, biopsy, and treatment.
- You want Medicare billing codes to offset part of the cost.
Choose Riverain Technologies if
- Your radiologists want detection help on chest CT and X-ray in their usual viewer.
- You read a high volume of chest X-rays as well as CT.
- You use RapidAI's enterprise platform and want chest tools added to it.
Verdict
The two score almost the same, and they solve different problems. Optellum fits health systems building a lung nodule program that ends in biopsy and treatment decisions, and Riverain fits radiology groups that want detection support on every chest read.
Some systems will want both, so ask each how its results reach the other team.
Where the two tools are headed in 2027 and beyond
Optellum: Optellum expanded to Tanner Health in Georgia on June 10, 2026, and announced plans to collaborate with Coreline Soft across the lung nodule pathway on August 13, 2026.
Riverain Technologies: Riverain Technologies made its ClearRead chest suite available through RapidAI's enterprise platform on October 6, 2026.
Methodology
Each row comes from the HIR reviews of Optellum and Riverain Technologies, scored under the HIR method, and from each vendor's public pricing where it exists. Any published price for Optellum or Riverain Technologies was checked on that vendor's own site on October 19, 2026.
A green check marks a clear edge for Optellum or Riverain Technologies only where their review scores differ by at least 0.3 points or the two reviews show a plain difference. Rows with nothing published for either Optellum or Riverain Technologies are left out, and time to full value for each adds up the rollout stages in its review.
Sources
- HIR review of Optellum and HIR review of Riverain Technologies
- Optellum website
- Riverain Technologies website
- Tanner Health and Optellum, June 10, 2026
- Optellum and Coreline Soft, August 13, 2026
- Riverain Technologies brings ClearRead to RapidAI, October 6, 2026